Physician profile
Amanda Marn
NPI 1790006286
$1,802.25
in general payments reported to CMS, 2019-2025
18 companies · $410 in 2025
The $410 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2022: $329 · 2023: $475 · 2024: $459 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,324.14 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $376.67 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.51 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $163.41 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $162.34 | 2019-2024 | Lifevest |
| Abiomed | $141.81 | 2024-2025 | Impella |
| Amgen INC. | $119.71 | 2022-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $89.28 | 2022 | |
| Merck Sharp & Dohme LLC | $79.29 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $61.11 | 2023 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $61.05 | 2022-2024 | |
| Esperion Therapeutics, INC. | $46.87 | 2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $37.09 | 2023 | Xarelto |
| Alnylam Pharmaceuticals INC. | $30.38 | 2025 | Amvuttra |
| Ionis Pharmaceuticals, INC. | $29.51 | 2025 | Tryngolza |
| Lexicon Pharmaceuticals, INC. | $21.79 | 2023 | Inpefa |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $21.56 | 2023 | Brilinta |
| Novo Nordisk INC | $20.02 | 2025 | Wegovy |
| Philips North America LLC | $16.85 | 2024 | (Ck7) Extended Holter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Marn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.